Insulet PODD posted solid second-quarter results that were largely consistent with our expectations, and our small adjustments to our underlying assumptions weren’t enough to move the needle on ...
Tandem Diabetes reported fourth-quarter and full-year results that slightly exceeded our revenue projections, but also exceeded our operating expense estimates. We're leaving our $32 fair value ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results